Annual SG&A
$8.54 M
-$1.69 M-16.55%
01 December 2023
Summary:
Plus Therapeutics annual selling, general & administrative expenses is currently $8.54 million, with the most recent change of -$1.69 million (-16.55%) on 01 December 2023. During the last 3 years, it has risen by +$2.14 million (+33.37%). PSTV annual SG&A is now -69.80% below its all-time high of $28.29 million, reached on 31 December 2011.PSTV Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$2.40 M
+$194.00 K+8.81%
01 September 2024
Summary:
Plus Therapeutics quarterly selling, general & administrative expenses is currently $2.40 million, with the most recent change of +$194.00 thousand (+8.81%) on 01 September 2024. Over the past year, it has increased by +$20.00 thousand (+0.84%). PSTV quarterly SG&A is now -69.52% below its all-time high of $7.86 million, reached on 30 June 2011.PSTV Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$1.94 B
-$12.88 M-0.67%
01 September 2024
Summary:
Plus Therapeutics TTM selling, general & administrative expenses is currently -$1.94 billion, with the most recent change of -$12.88 million (-0.67%) on 01 September 2024. Over the past year, it has dropped by -$1.95 billion (-22812.32%). PSTV TTM SG&A is now -8947.65% below its all-time high of $28.71 million, reached on 30 September 2011.PSTV TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PSTV Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +0.8% | -10000.0% |
| 3 y3 years | +33.4% | +20.4% | -10000.0% |
| 5 y5 years | +37.3% | +104.9% | -10000.0% |
PSTV Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -16.6% | +33.4% | -33.1% | +24.6% | -10.8% | at low |
| 5 y | 5 years | -16.6% | +61.5% | -33.1% | +126.1% | -15.2% | at low |
| alltime | all time | -69.8% | +960.0% | -69.5% | +146.6% | -8947.6% | at low |
Plus Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $2.40 M(+8.8%) | $9.19 M(+4.5%) |
| June 2024 | - | $2.20 M(-0.5%) | $8.79 M(+3.3%) |
| Mar 2024 | - | $2.21 M(-6.9%) | $8.51 M(-0.4%) |
| Dec 2023 | $8.54 M(-16.5%) | $2.38 M(+19.0%) | $8.54 M(-12.4%) |
| Sept 2023 | - | $2.00 M(+3.8%) | $9.75 M(-2.2%) |
| June 2023 | - | $1.92 M(-14.3%) | $9.98 M(-3.5%) |
| Mar 2023 | - | $2.25 M(-37.4%) | $10.34 M(+1.0%) |
| Dec 2022 | $10.24 M(+49.4%) | $3.58 M(+61.3%) | $10.24 M(+17.7%) |
| Sept 2022 | - | $2.22 M(-2.9%) | $8.69 M(+2.7%) |
| June 2022 | - | $2.29 M(+6.9%) | $8.46 M(+10.7%) |
| Mar 2022 | - | $2.14 M(+4.8%) | $7.64 M(+11.5%) |
| Dec 2021 | $6.85 M(+7.0%) | $2.04 M(+2.6%) | $6.85 M(-3.6%) |
| Sept 2021 | - | $1.99 M(+35.5%) | $7.11 M(+15.0%) |
| June 2021 | - | $1.47 M(+8.7%) | $6.18 M(+0.7%) |
| Mar 2021 | - | $1.35 M(-41.2%) | $6.14 M(-4.2%) |
| Dec 2020 | $6.41 M(+21.1%) | $2.30 M(+116.9%) | $6.41 M(+10.8%) |
| Sept 2020 | - | $1.06 M(-25.8%) | $5.78 M(-1.9%) |
| June 2020 | - | $1.43 M(-11.7%) | $5.89 M(+8.4%) |
| Mar 2020 | - | $1.62 M(-3.2%) | $5.43 M(+2.7%) |
| Dec 2019 | $5.29 M(-15.0%) | $1.67 M(+42.9%) | $5.29 M(+14.9%) |
| Sept 2019 | - | $1.17 M(+20.4%) | $4.61 M(-5.8%) |
| June 2019 | - | $972.00 K(-34.2%) | $4.89 M(-17.3%) |
| Mar 2019 | - | $1.48 M(+49.6%) | $5.91 M(-19.6%) |
| Dec 2018 | $6.22 M(-44.4%) | $987.00 K(-32.2%) | $7.36 M(-13.5%) |
| Sept 2018 | - | $1.46 M(-27.0%) | $8.50 M(-12.1%) |
| June 2018 | - | $1.99 M(-31.8%) | $9.67 M(-12.5%) |
| Mar 2018 | - | $2.92 M(+37.1%) | $11.06 M(-1.1%) |
| Dec 2017 | $11.19 M(-8.1%) | $2.13 M(-18.8%) | $11.19 M(-5.7%) |
| Sept 2017 | - | $2.63 M(-22.4%) | $11.86 M(-1.7%) |
| June 2017 | - | $3.38 M(+11.0%) | $12.07 M(+1.4%) |
| Mar 2017 | - | $3.05 M(+8.5%) | $11.90 M(-2.3%) |
| Dec 2016 | $12.17 M(-2.0%) | $2.81 M(-0.7%) | $12.18 M(+0.9%) |
| Sept 2016 | - | $2.83 M(-12.1%) | $12.07 M(-0.9%) |
| June 2016 | - | $3.22 M(-3.1%) | $12.18 M(-1.9%) |
| Mar 2016 | - | $3.32 M(+22.7%) | $12.41 M(-0.1%) |
| Dec 2015 | $12.43 M(-44.4%) | $2.71 M(-7.8%) | $12.43 M(-8.8%) |
| Sept 2015 | - | $2.94 M(-14.8%) | $13.63 M(-16.6%) |
| June 2015 | - | $3.45 M(+3.3%) | $16.34 M(-15.9%) |
| Mar 2015 | - | $3.34 M(-14.5%) | $19.43 M(-13.1%) |
| Dec 2014 | $22.36 M(-10.8%) | $3.91 M(-30.9%) | $22.36 M(-10.0%) |
| Sept 2014 | - | $5.65 M(-13.6%) | $24.83 M(-1.8%) |
| June 2014 | - | $6.54 M(+4.3%) | $25.30 M(+0.3%) |
| Mar 2014 | - | $6.27 M(-1.7%) | $25.22 M(+0.7%) |
| Dec 2013 | $25.06 M(-0.4%) | $6.38 M(+4.3%) | $25.06 M(+0.5%) |
| Sept 2013 | - | $6.12 M(-5.2%) | $24.94 M(-0.4%) |
| June 2013 | - | $6.46 M(+5.8%) | $25.05 M(+0.3%) |
| Mar 2013 | - | $6.10 M(-2.6%) | $24.96 M(-0.8%) |
| Dec 2012 | $25.16 M | $6.26 M(+0.6%) | $25.16 M(-0.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2012 | - | $6.23 M(-2.2%) | $25.39 M(-3.5%) |
| June 2012 | - | $6.37 M(+1.1%) | $26.32 M(-5.4%) |
| Mar 2012 | - | $6.30 M(-3.0%) | $27.82 M(-1.7%) |
| Dec 2011 | $28.29 M(+19.8%) | $6.50 M(-9.2%) | $28.29 M(-1.5%) |
| Sept 2011 | - | $7.16 M(-9.0%) | $28.71 M(+4.2%) |
| June 2011 | - | $7.86 M(+16.1%) | $27.55 M(+9.5%) |
| Mar 2011 | - | $6.77 M(-2.2%) | $25.16 M(+6.6%) |
| Dec 2010 | $23.61 M(+38.9%) | $6.92 M(+15.5%) | $23.61 M(+7.2%) |
| Sept 2010 | - | $5.99 M(+9.4%) | $22.03 M(+9.4%) |
| June 2010 | - | $5.48 M(+5.0%) | $20.14 M(+9.2%) |
| Mar 2010 | - | $5.22 M(-2.3%) | $18.43 M(+8.5%) |
| Dec 2009 | $17.00 M(+4.1%) | $5.34 M(+30.2%) | $17.00 M(+11.6%) |
| Sept 2009 | - | $4.10 M(+8.8%) | $15.23 M(-1.9%) |
| June 2009 | - | $3.77 M(-0.2%) | $15.53 M(-3.2%) |
| Mar 2009 | - | $3.78 M(+5.7%) | $16.04 M(-1.8%) |
| Dec 2008 | $16.33 M(-3.1%) | $3.58 M(-18.8%) | $16.33 M(-10.1%) |
| Sept 2008 | - | $4.41 M(+3.0%) | $18.16 M(+3.5%) |
| June 2008 | - | $4.28 M(+5.2%) | $17.54 M(+1.9%) |
| Mar 2008 | - | $4.07 M(-24.7%) | $17.21 M(+2.1%) |
| Dec 2007 | $16.86 M(+15.4%) | $5.40 M(+42.5%) | $16.86 M(+16.5%) |
| Sept 2007 | - | $3.79 M(-4.1%) | $14.47 M(-0.0%) |
| June 2007 | - | $3.95 M(+6.5%) | $14.47 M(-0.9%) |
| Mar 2007 | - | $3.71 M(+23.2%) | $14.60 M(-0.0%) |
| Dec 2006 | $14.60 M(+24.2%) | $3.01 M(-20.5%) | $14.60 M(-6.6%) |
| Sept 2006 | - | $3.79 M(-7.1%) | $15.63 M(+5.9%) |
| June 2006 | - | $4.08 M(+9.8%) | $14.76 M(+12.0%) |
| Mar 2006 | - | $3.72 M(-7.9%) | $13.17 M(+10.6%) |
| Dec 2005 | $11.76 M(+31.1%) | $4.04 M(+38.3%) | $11.91 M(+13.8%) |
| Sept 2005 | - | $2.92 M(+16.9%) | $10.47 M(+10.1%) |
| June 2005 | - | $2.50 M(+1.7%) | $9.51 M(+2.9%) |
| Mar 2005 | - | $2.46 M(-5.3%) | $9.24 M(+3.0%) |
| Dec 2004 | $8.96 M(-0.4%) | $2.60 M(+32.7%) | $8.96 M(+4.4%) |
| Sept 2004 | - | $1.96 M(-12.2%) | $8.59 M(-5.8%) |
| June 2004 | - | $2.23 M(+2.1%) | $9.11 M(+3.1%) |
| Mar 2004 | - | $2.18 M(-1.6%) | $8.84 M(-1.8%) |
| Dec 2003 | $9.00 M(+13.3%) | $2.22 M(-10.6%) | $9.00 M(-0.8%) |
| Sept 2003 | - | $2.48 M(+26.9%) | $9.07 M(+5.8%) |
| June 2003 | - | $1.96 M(-16.6%) | $8.57 M(+0.9%) |
| Mar 2003 | - | $2.34 M(+2.2%) | $8.50 M(+38.1%) |
| Dec 2002 | $7.94 M(-1.6%) | $2.29 M(+15.7%) | $6.16 M(+14.4%) |
| Sept 2002 | - | $1.98 M(+5.3%) | $5.38 M(-5.1%) |
| June 2002 | - | $1.88 M(+23.9%) | $5.67 M(-7.6%) |
| Dec 2001 | $8.07 M(+55.7%) | $1.52 M(-33.1%) | $6.13 M(+32.9%) |
| Sept 2001 | - | $2.27 M(-3.2%) | $4.61 M(+96.8%) |
| June 2001 | - | $2.34 M | $2.34 M |
| Dec 2000 | $5.18 M(+41.3%) | - | - |
| Dec 1999 | $3.67 M(+355.2%) | - | - |
| Dec 1998 | $806.00 K | - | - |
FAQ
- What is Plus Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Plus Therapeutics?
- What is Plus Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Plus Therapeutics?
- What is Plus Therapeutics quarterly SG&A year-on-year change?
- What is Plus Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Plus Therapeutics?
- What is Plus Therapeutics TTM SG&A year-on-year change?
What is Plus Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of PSTV is $8.54 M
What is the all time high annual SG&A for Plus Therapeutics?
Plus Therapeutics all-time high annual selling, general & administrative expenses is $28.29 M
What is Plus Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of PSTV is $2.40 M
What is the all time high quarterly SG&A for Plus Therapeutics?
Plus Therapeutics all-time high quarterly selling, general & administrative expenses is $7.86 M
What is Plus Therapeutics quarterly SG&A year-on-year change?
Over the past year, PSTV quarterly selling, general & administrative expenses has changed by +$20.00 K (+0.84%)
What is Plus Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of PSTV is -$1.94 B
What is the all time high TTM SG&A for Plus Therapeutics?
Plus Therapeutics all-time high TTM selling, general & administrative expenses is $28.71 M
What is Plus Therapeutics TTM SG&A year-on-year change?
Over the past year, PSTV TTM selling, general & administrative expenses has changed by -$1.95 B (-22812.32%)